 |
 Video: What is a Stock Split?
|
|
|
| Sana Biotechnology is a biotechnology company, focusing on utilizing engineered cells as medicines. Co. is developing ex vivo and in vivo cell engineering platforms for treatment across therapeutic areas including oncology, diabetes, central nervous system disorders, cardiovascular diseases, and genetic disorders, among others. Co.'s ex vivo cell engineering pipeline includes its allogeneic T cell program that target CD19 to treat patients with refractory lymphoma. Co.'s in vivo cell engineering pipeline includes its CAR T cell fusosome product candidates (SG242, SG295) target CD19+ cancer cells, including non-Hodgkin lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. According to our Sana Biotechnology stock split history records, Sana Biotechnology has had 0 splits. | |
|
Sana Biotechnology (SANA) has 0 splits in our Sana Biotechnology stock split history database.
Looking at the Sana Biotechnology stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Sana Biotechnology shares, starting with a $10,000 purchase of SANA, presented on a split-history-adjusted basis factoring in the complete Sana Biotechnology stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
02/05/2021 |
|
| End date: |
04/26/2024 |
|
| Start price/share: |
$39.12 |
|
| End price/share: |
$8.72 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-77.71% |
|
| Average Annual Total Return: |
-37.27% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$2,228.62 |
|
| Years: |
3.22 |
|
|
|
|
|
